Lipid Nanoparticle Drug Delivery Advances, March 23-30, 2025
- aprilt97
- Mar 31
- 2 min read
News Summaries
Serina Therapeutics: Presented preclinical data on non-immunogenic POZ-lipid technology at the ACS Spring 2025 Meeting.
Genevant Sciences and Arbutus Biopharma: Initiated international patent infringement lawsuits against Moderna over LNP technology.
CMN Weekly: Reported interim Phase 1 trial results for YOLT-203, an LNP-CRISPR therapy for primary hyperoxaluria type 1.
Detailed News Summaries
Serina Therapeutics: Non-Immunogenic POZ-Lipid Technology
Serina Therapeutics presented preclinical data at the American Chemical Society (ACS) Spring 2025 Meeting demonstrating that its proprietary POZ-lipid technology avoids immune responses in rats. Unlike traditional PEGylated lipids, POZ-LNPs did not trigger IgM or IgG antibodies upon repeated dosing, addressing safety concerns linked to PEG-related immunogenicity. The technology enhances the potential for long-term therapeutic applications, particularly in neurological diseases.
Release Date: March 24, 2025
Location: Huntsville, Alabama, USA
Genevant Sciences and Arbutus Biopharma: Patent Litigation Against Moderna
Genevant Sciences and Arbutus Biopharma filed five lawsuits in Canada, Japan, Switzerland, and the Unified Patent Court (UPC) against Moderna for alleged infringement of LNP patents. The cases target Moderna’s Spikevax® and mRESVIA® products, which reportedly use lipid compositions protected under Genevant and Arbutus patents. Testing of commercial Moderna samples confirmed the presence of LNPs covered by the disputed patents.
Release Date: March 23, 2025
Genevant Sciences: Basel, Switzerland
Arbutus Biopharma: Warminster, Pennsylvania, USA
CMN Weekly: YOLT-203 Phase 1 Trial Update
CMN Weekly reported interim results from an ongoing Phase 1 trial of YOLT-203, an LNP-delivered CRISPR-Cas12 therapy for primary hyperoxaluria type 1 (PH1). Seven patients dosed with 0.3–0.45 mg/kg exhibited up to 75% reduction in urinary oxalate levels, comparable to siRNA therapies requiring quarterly dosing. The therapy showed no serious adverse events, with transient liver enzyme elevations resolving within days. The trial, conducted in China, highlights the potential of single-dose LNP-CRISPR treatments for metabolic disorders.
Release Date: March 26, 2025
Website Link: https://crisprmedicinenews.com/news/cmn-weekly-28-march-2025-your-weekly-crispr-medicine-news/
Authors: Karen O’Hanlon Cohrt (CMN Weekly)
Related Institute: Investigator-initiated trial in China
Conclusion
The week of March 23–30, 2025, saw critical progress in LNP technology, spanning novel lipid chemistries, clinical advancements, and intellectual property disputes. Serina’s POZ-lipid innovation promises safer gene therapies, while YOLT-203’s clinical progress underscores the therapeutic potential of CRISPR-LNP systems. The Moderna litigation highlights the growing commercialization of LNP platforms and the importance of robust patent frameworks in fostering innovation.
Comments